Drug combination shows potent punch against HIV in children

December 14, 1999

Philadelphia, Pa. - A study headed by a physician at The Children's Hospital of Philadelphia has shown that a novel combination of drugs achieves strong, sustained results in controlling HIV infection in children, according to an article in the December 16 New England Journal of Medicine. Forty-eight weeks after the treatment began, the virus, which causes AIDS, remained at undetectable levels in more than half the children studied. "These impressive results expand our treatment options for HIV-infected children," said Stuart E. Starr, M.D., chief of Immunologic and Infectious Diseases at The Children's Hospital of Philadelphia, the lead author and chair of the multicenter study. The fact that one of the drugs, efavirenz, is taken only once a day is a step toward simplifying the complicated, often difficult treatment regimen for children with HIV.

One novel feature of the trial was that levels of efavirenz and another drug, nelfinavir, were measured in each child's bloodstream during the course of the study, and subsequent doses were individually adjusted to aim for better results in fighting the virus. Often in clinical trials, drug doses are standardized and remain the same throughout the study period.

The study was conducted in 57 HIV-infected children age 3 to 16 at 18 sites participating in the Pediatric AIDS Clinical Trial Group. The children received a combination of the drugs efavirenz, nelfinavir and one or more drugs called nucleoside reverse transcriptase inhibitors (NRTIs). Nearly all of the children had earlier been treated with NRTIs, a class of drugs that includes AZT and ddI. The virus was considered to be at undetectable levels if tests that detect as few as 50 copies of virus particles in each milliliter of blood were negative. Before the study, the children had more than 400 particles per milliliter, enough to cause signs such as failure to thrive and an enlarged liver. Children with undetectable HIV levels, said Dr. Starr, usually have minor or no signs of the disease, and they gain weight and have better appetites. Serious side effects were uncommon, although some children experienced rashes or diarrhea.

Although in the past few years, combinations of anti-HIV drugs have shown considerable progress in suppressing the AIDS virus in adults, consistent results were more difficult to achieve in children. Furthermore, compared to adult medications, fewer anti-HIV drugs have been available for children. "Our favorable results indicate that a high proportion of children can attain undetectable levels of AIDS virus when a potent combination of anti-HIV drugs is used," said Dr. Starr. Interim results from the study, reported last year after 20 weeks of treatment, led the U.S. Food and Drug Administration to approve efavirenz (trade name Sustiva(r)) in September 1998 for use in children. The current results reinforce those earlier findings.

Anti-HIV drugs are classified by the viral enzymes they inhibit, thus interfering with the virus' ability to reproduce. The NRTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz both act against the enzyme reverse transcriptase, but have different chemical structures. Nelfinavir, another drug used in the study, is a protease inhibitor, which targets the enzyme protease.

Efavirenz is taken only once a day, in contrast to other drugs in the combination therapy, which require 3 to 4 doses daily. A more convenient regimen would make it easier for children to comply with the treatment, and said Dr. Starr, "we're still looking for an overall combination of drugs that is easier for children to take." Further studies by the Pediatric AIDS Clinical Trials Group will study long-term effectiveness of the drug combinations, as well as results in adolescents and in children aged 2 to 8.
The Children's Hospital of Philadelphia, the nation's first children's hospital, is a world-renowned leader in patient care, education and research. This 373-bed multispecialty hospital provides comprehensive pediatric services, including home care, to children from before birth through age 19. The hospital has more than 17,000 admissions, and provides care in more than 600,000 outpatient visits annually.

Children's Hospital of Philadelphia

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.